Formulation:

Boswellia has most often been studied as an oral capsule.^[1] Some studies have used concentrations of 12.5%–20% of boswellic acids.^[2][1]

In one study where Boswellia was used topically, it was specified that the formulation was 40% boswellic acids.^[3]

Range of dosages studied:

Boswellia has been most often studied at dosages of 100–250 mg/day of the Aflapin and 5-Loxin formulations.^[1][4] Nonproprietary extracts have been studied at higher dosages, between 1,000 and 2,400 mg/day.^[3][5][6][7]

Effective dosages:

Osteoarthritis

Often older adults (ages 50–65): 100–250 mg/day of oral capsules for 3 months.^[1][4][8]

Special considerations: The formulations Aflapin and 5-Loxin have most often been studied. In a 2024 meta-analysis, subgroup analyses found Aflapin to have greater improvements in pain, functioning, and stiffness scores compared to a placebo.^[1]

Traumatic brain injury and stroke recovery

Adults (average age of 36): 1,200–2,400 mg/day of a Boswellia extract for 3 months.^[6][7]

Special considerations: Participants with a traumatic brain injury had an average time of 13 months since their injury.^[6] In another trial, where Boswellia was used within 24 hours of hospital admission after a traumatic brain injury, there was no effect.^[5]